Aggregate additional revenue recognition milestone method revenue eligible to receive.

No definition available.

Name:	sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Agreement Termination, Term

+ References

No definition available.

+ Details

Name:	sgmo_AgreementTerminationTerm
Namespace Prefix:	sgmo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaboration and license agreements number of products approved under agreement.

+ References

No definition available.

+ Details

Name:	sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Number Of Milestones Achieved

+ References

No definition available.

+ Details

Name:	sgmo_CollaborativeArrangementNumberOfMilestonesAchieved
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Research Service Fees

+ References

No definition available.

+ Details

Name:	sgmo_CollaborativeArrangementResearchServiceFees
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative arrangement transaction price.

+ References

No definition available.

+ Details

Name:	sgmo_CollaborativeArrangementTransactionPrice
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty

+ References

No definition available.

+ Details

Name:	sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty
Namespace Prefix:	sgmo_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Customer contract liability milestone payment eligible to receive.

+ References

No definition available.

+ Details

Name:	sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payments received.

+ References

No definition available.

+ Details

Name:	sgmo_MilestonePaymentsReceived
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone revenue receivable.

+ References

No definition available.

+ Details

Name:	sgmo_MilestoneRevenueReceivable
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number of clinical or regulatory milestones included in transaction price.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483041/730-20-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerSB525Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details) $ in Millions	1 Months Ended			12 Months Ended	70 Months Ended	77 Months Ended
	Sep. 30, 2020 USD ($)	Dec. 31, 2017 USD ($)	May 31, 2017 USD ($) milestone	Dec. 31, 2020 USD ($)	Sep. 30, 2023 USD ($) milestone product	Sep. 30, 2023 USD ($) milestone
Pfizer Inc.
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Agreement termination, term			15 years
Pfizer Inc. \| S B Five Two Five And Other Products
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement			$ 70.0
Potential amount to be funded for achievement of specified commercialized and sales milestones			266.5
Pfizer Inc. \| S B Five Two Five And Other Products \| Achievement of specified clinical development intellectual property and regulatory milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Development and sales-based milestone payments to be received			208.5
Pfizer Inc. \| S B Five Two Five
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone revenue receivable			220.0
Pfizer Inc. \| Other products
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone revenue receivable			$ 175.0
Pfizer Inc. \| License \| Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of net sales per developed licensed product which will trigger royalties by counterparty		14.00%	14.00%
Pfizer Inc. \| License \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Percentage of net sales per developed licensed product which will trigger royalties by counterparty		20.00%	20.00%
Pfizer Inc. \| C9ORF72
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement		$ 5.0		$ 5.0
Development and sales-based milestone payments to be received	$ 5.0
Collaborative arrangement transaction price		$ 17.0
Pfizer SB-525
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement			$ 55.0
Collaborative arrangement transaction price			134.0
Research service fees			$ 79.0
Pfizer SB-525 \| S B Five Two Five And Other Products
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Collaborative arrangement, number of milestones achieved \| milestone			2			2
Milestone payments received						$ 55.0
Pfizer C9ORF72
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Agreement termination, term		15 years
Pfizer C9ORF72 \| C9ORF72
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement		$ 12.0
Milestone payments received		12.0			$ 5.0
Number of products approved \| product					0
Number of milestones included in transaction price \| milestone					0
Pfizer C9ORF72 \| C9ORF72 \| Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Development and sales-based milestone payments to be received		60.0
Pfizer C9ORF72 \| C9ORF72 \| Achievement Of Commercial Milestones \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Development and sales-based milestone payments to be received		$ 90.0